Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2024

Open Access 01-12-2024 | SARS-CoV-2 | Correspondence

Identification of SARS-CoV-2-specific T cell and its receptor

Authors: Qian Zhang, Qing Liang, Rui Zhang, Nan Wang, Xu Xiao, Jiahao Shao, Kejia Wang

Published in: Journal of Hematology & Oncology | Issue 1/2024

Login to get access

Abstract

The T-cell receptor (TCR) repertoires exhibits distinct signatures associated with COVID-19 severity. However, the precise identification of vaccine-induced SARS-CoV-2-specific TCRs and T-cell immunity mechanisms are unknown. We developed a machine-learning model that can differentiate COVID-19 patients from healthy individuals based on TCR sequence features with an accuracy of 95.7%. Additionally, we identified SARS-CoV-2-specific T cells and TCR in HLA-A*02 vaccinated individuals by peptide stimulation. The SARS-CoV-2-specific T cells exhibited higher cytotoxicity and prolonged survival when targeting spike-pulsed cells in vitro or in vivo. The top-performing TCR was further tested for its affinity and cytotoxic effect against SARS-CoV-2-associated epitopes. Furthermore, single-cell RNA sequencing (scRNA-seq), immune repertoire sequencing (IR-seq) and flow cytometry were used to access vaccine-induced cellular immunity, which demonstrated that robust T cell responses (T cell activation, tissue-resident memory T cell (Trm) generation, and TCR clonal expansion) could be induced by intranasal vaccination. In summary, we identified the SARS-CoV-2-associated TCR repertoires profile, specific TCRs and T cell responses. This study provides a theoretical basis for developing effective immunization strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–e23839.CrossRefPubMedPubMedCentral Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–e23839.CrossRefPubMedPubMedCentral
2.
go back to reference Rooney A, Bivona C, Liu B, Streeter D, Gong H, Khan Q. Risk of SARS-CoV-2 breakthrough infection in Vaccinated Cancer patients: a retrospective cohort study. J Hematol Oncol. 2022;15:67.CrossRefPubMedPubMedCentral Rooney A, Bivona C, Liu B, Streeter D, Gong H, Khan Q. Risk of SARS-CoV-2 breakthrough infection in Vaccinated Cancer patients: a retrospective cohort study. J Hematol Oncol. 2022;15:67.CrossRefPubMedPubMedCentral
3.
go back to reference Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature. 2022;601:617–22.CrossRefPubMed Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature. 2022;601:617–22.CrossRefPubMed
4.
go back to reference Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to Omicron. Cell. 2022;185:847–e85911.CrossRefPubMedPubMedCentral Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to Omicron. Cell. 2022;185:847–e85911.CrossRefPubMedPubMedCentral
5.
go back to reference Zhang J-Y, Wang X-M, Xing X, Xu Z, Zhang C, Song J-W, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21:1107–18.CrossRefPubMed Zhang J-Y, Wang X-M, Xing X, Xu Z, Zhang C, Song J-W, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21:1107–18.CrossRefPubMed
6.
go back to reference Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures Associated with Severity of Disease. Immunity. 2020;53:442–e4554.CrossRefPubMedPubMedCentral Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures Associated with Severity of Disease. Immunity. 2020;53:442–e4554.CrossRefPubMedPubMedCentral
7.
go back to reference Zhang T, Tian W, Wei S, Lu X, An J, He S, et al. Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Exp Hematol Oncol. 2023;12:66.CrossRefPubMedPubMedCentral Zhang T, Tian W, Wei S, Lu X, An J, He S, et al. Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Exp Hematol Oncol. 2023;12:66.CrossRefPubMedPubMedCentral
8.
go back to reference Wada D, Nakamori Y, Maruyama S, Shimazu H, Saito F, Yoshiya K, et al. Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection. Exp Hematol Oncol. 2022;11:53.CrossRefPubMedPubMedCentral Wada D, Nakamori Y, Maruyama S, Shimazu H, Saito F, Yoshiya K, et al. Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection. Exp Hematol Oncol. 2022;11:53.CrossRefPubMedPubMedCentral
Metadata
Title
Identification of SARS-CoV-2-specific T cell and its receptor
Authors
Qian Zhang
Qing Liang
Rui Zhang
Nan Wang
Xu Xiao
Jiahao Shao
Kejia Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2024
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-024-01537-6

Other articles of this Issue 1/2024

Journal of Hematology & Oncology 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine